Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares in open market trade

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $70.46 per share. After this transaction, he directly holds 385,330 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares ($528,450)

Net Sell 3 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($528K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,500	$70.46	$528K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 385,330 shares (Direct, null); Common Stock — 2,083 shares (Indirect, by Trust 1)

Footnotes (1)

Shares held by The Bridget Blum 2003 Irrevocable Trust. Shares held by The Brittany Blum 2003 Irrevocable Trust.

Key Figures

Shares sold: 7,500 shares Sale price per share: $70.46 per share Direct holdings after transaction: 385,330 shares +2 more

5 metrics

Shares sold 7,500 shares Open-market sale of common stock

Sale price per share $70.46 per share Price for 7,500-share sale

Direct holdings after transaction 385,330 shares Common stock held directly after sale

Bridget Blum Trust holdings 2,083 shares Indirect ownership by The Bridget Blum 2003 Irrevocable Trust

Brittany Blum Trust holdings 2,083 shares Indirect ownership by The Brittany Blum 2003 Irrevocable Trust

Key Terms

open-market sale, indirect ownership, Irrevocable Trust

3 terms

open-market sale financial

"reported an open-market sale of 7,500 shares of common stock at $70.46 per share"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust"

Irrevocable Trust financial

"held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 04:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		S		7,500	D	$70.46	385,330	D
Common Stock								2,083	I	by Trust 1⁽¹⁾
Common Stock								2,083	I	by Trust 2⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CYTOKINETICS (CYTK) CEO Robert Blum report?

Robert Blum reported an open-market sale of 7,500 CYTOKINETICS (CYTK) common shares at $70.46 per share. This Form 4 filing records the transaction and updates his reported ownership position with the company’s stock.

At what price were the CYTOKINETICS (CYTK) shares sold in the Form 4?

The 7,500 CYTOKINETICS (CYTK) common shares were sold at $70.46 per share. This represents an open-market sale, as disclosed in the Form 4 transaction details for Robert Blum.

How many CYTOKINETICS (CYTK) shares does Robert Blum hold after this Form 4 sale?

Following the sale, Robert Blum directly holds 385,330 CYTOKINETICS (CYTK) common shares. This updated figure reflects his remaining direct ownership stake reported in the Form 4 filing after the 7,500-share transaction.

What indirect CYTOKINETICS (CYTK) holdings are reported for Robert Blum?

The filing reports 2,083 CYTOKINETICS (CYTK) shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, both reported as indirect ownership interests.

Does the CYTOKINETICS (CYTK) Form 4 show any derivative security activity?

The Form 4 shows no derivative security transactions for CYTOKINETICS (CYTK). The derivative summary is empty, indicating no reported option exercises, conversions, or other derivative-related activities in this filing.